Using the long-running, U.S.-based Health and Retirement Study (HRS), which enrolls people age 50 and older, as the data source, Ross Wilkie, PhD, of Keele University in Staffordshire, England, and colleagues estimated that those reporting an arthritis diagnosis could expect just 6.18 more years of being able to work without physical limitations, compared with 11.71 years for those without arthritis.

Due to the complexity of SLE, rheumatology providers should take an active role in assessing reproductive health, providing education on how SLE may affect pregnancy, and taking a collaborative, multidisciplinary approach with the patient’s gynecologist.

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer. Researchers used 2000–2023 data for RA patients from the BIOBADASER III registry, a multicentre national registry of patients treated with b/tsDMARDs. 

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.